Septerna (NASDAQ:SEPN) Reaches New 1-Year Low – Time to Sell?

Septerna, Inc. (NASDAQ:SEPN) shares reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $4.17 and last traded at $6.87, with a volume of 8617193 shares changing hands. The stock had previously closed at $12.96.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on SEPN shares. TD Cowen began coverage on shares of Septerna in a research report on Tuesday, November 19th. They set a “buy” rating on the stock. JPMorgan Chase & Co. assumed coverage on shares of Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $50.00 target price on shares of Septerna in a research note on Tuesday, February 11th. Finally, Wells Fargo & Company cut Septerna from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $43.00 to $14.00 in a research note on Tuesday.

Septerna Trading Down 47.0 %

The company has a 50 day simple moving average of $18.82.

Hedge Funds Weigh In On Septerna

Hedge funds have recently bought and sold shares of the company. Tower Research Capital LLC TRC bought a new position in Septerna during the 4th quarter worth approximately $25,000. New York State Common Retirement Fund acquired a new stake in shares of Septerna during the 4th quarter valued at approximately $32,000. Legal & General Group Plc bought a new position in Septerna during the fourth quarter worth $42,000. Summit Investment Advisors Inc. acquired a new position in Septerna in the fourth quarter worth $45,000. Finally, BNP Paribas Financial Markets bought a new stake in Septerna during the fourth quarter valued at $52,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.